Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cohen

Showing results (1001-1010 of 1,023) with videos related to

Pageof 103
Sort By:
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
Journal for Immunotherapy of Cancer|November 3, 2024
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT studyKevin C Flanagan, Jon Earls, Jeffrey Hiken, et al.
Cell Reports|July 8, 2021
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjectsMadeleine F Jennewein, Anna J MacCamy, Nicholas R Akins, et al.
Iscience|April 22, 2026
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humansDaniel J Schuster, Shuying S Li, Dieter Mielke, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
Science Translational Medicine|May 24, 2023
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responsesKristen W Cohen, Stephen C De Rosa, William J Fulp, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2021
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ SubjectsMadeleine F Jennewein, Anna J MacCamy, Nicholas R Akins, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2021
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cellsKristen W Cohen, Susanne L Linderman, Zoe Moodie, et al.
Cell Reports. Medicine|July 12, 2021
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cellsKristen W Cohen, Susanne L Linderman, Zoe Moodie, et al.
Pageof 103

Showing results (1001-1010 of 1,023) with videos related to

Sort By:
Pageof 103
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
Journal for Immunotherapy of Cancer|November 3, 2024
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT studyKevin C Flanagan, Jon Earls, Jeffrey Hiken, et al.
Cell Reports|July 8, 2021
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjectsMadeleine F Jennewein, Anna J MacCamy, Nicholas R Akins, et al.
Iscience|April 22, 2026
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humansDaniel J Schuster, Shuying S Li, Dieter Mielke, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
Science Translational Medicine|May 24, 2023
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responsesKristen W Cohen, Stephen C De Rosa, William J Fulp, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2021
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ SubjectsMadeleine F Jennewein, Anna J MacCamy, Nicholas R Akins, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2021
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cellsKristen W Cohen, Susanne L Linderman, Zoe Moodie, et al.
Cell Reports. Medicine|July 12, 2021
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cellsKristen W Cohen, Susanne L Linderman, Zoe Moodie, et al.
Pageof 103